Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management

Eur Heart J Cardiovasc Pharmacother. 2021 May 23;7(3):e53-e54. doi: 10.1093/ehjcvp/pvaa049.

Authors

Giovanni Diana¹, Rocky Strollo², Davide Diana³, Mirko Strollo⁴, Alfredo R Galassi³, Filippo Crea¹

Affiliations

¹ Department of Cardiovascular Science, Università Cattolica del Sacro Cuore, Rome, Italy.
² Department of Medicine, Unit of Endocrinology & Diabetes, Università Campus Bio-Medico di Roma, Rome, Italy.
³ Department of PROMISE, University of Palermo, Palermo, Italy.
⁴ Department of Veterinary Medicine and Animal Productions, Università Federico II, Naples, Italy.

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / therapeutic use*
Azithromycin / therapeutic use
COVID-19 Drug Treatment*
Humans
Minocycline / therapeutic use*

Substances

Anti-Bacterial Agents
Azithromycin
Minocycline